Menu Search
Equities

ImmuPharma PLC

25I:MUN

ImmuPharma PLC

Actions
  • Price (EUR)0.024
  • Today's Change0.006 / 33.33%
  • Shares traded1.40k
  • 1 Year change+17.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 09:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

  • Revenue in GBP (TTM)-69.96k
  • Net income in GBP-2.46m
  • Incorporated2000
  • Employees5.00
  • Location
    ImmuPharma PLCOne Bartholomew CloseLONDON EC1A 7BLUnited KingdomGBR
  • Phone+44 207 152 4080
  • Fax+44 207 152 4001
  • Websitehttps://www.immupharma.co.uk/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.